Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial.

Autor: Dinkelborg, Katja1,2 (AUTHOR), Kahlhöfer, Julia1,3 (AUTHOR), Dörge, Petra1,3 (AUTHOR), Yurdaydin, Cihan4,5 (AUTHOR), Hardtke, Svenja3,6 (AUTHOR), Caruntu, Florin Alexandru7 (AUTHOR), Curescu, Manuela G.8 (AUTHOR), Yalcin, Kendal9 (AUTHOR), Akarca, Ulus S.10 (AUTHOR), Gürel, Selim11 (AUTHOR), Zeuzem, Stefan12 (AUTHOR), Erhardt, Andreas13 (AUTHOR), Lüth, Stefan6 (AUTHOR), Papatheodoridis, George V.14 (AUTHOR), Keskin, Onur4 (AUTHOR), Port, Kerstin1 (AUTHOR), Radu, Monica7 (AUTHOR), Celen, Mustafa K.9 (AUTHOR), Idilman, Ramazan4 (AUTHOR), Weber, Kristina15 (AUTHOR)
Zdroj: Liver International. Aug2023, Vol. 43 Issue 8, p1663-1676. 14p. 3 Charts, 6 Graphs.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje